header logo image


Page 532«..1020..531532533534..540550..»

Amid COVID 19 Crisis, Joshua Frase Foundation Leads Search Spanning Two Continents to Deliver Ventilator to Ailing Child in Ecuador – PRNewswire

May 27th, 2020 11:49 am

PONTE VEDRA BEACH, Fla., May 26, 2020 /PRNewswire/ --Throughout the pandemic, ventilator support has been in short supply. And for one family in Ecuador, finding a ventilator and getting it flown to the small hospital where their one-year-old son was being treated for a rare neuromuscular disorder seemed an insurmountable task.

But worlds away, two organizations on different continents used their network to not only find one, but get it donated and shipped in the nick of time all through families connected by the same thread -- having children affected by centronuclear and myotubular myopathy disorder.

One-month-old Wilson is now stable and ready to go home in Ecuador thanks the herculean efforts of Florida-based Joshua Frase Foundation and Zusammen Stark! eV (CNM-Together Strong), an association in Germany.

"The families that played a role in giving mechanical breath to this child know all too well the priceless value it holds, especially in that fragile first year with a child diagnosed with a nueromuscular disorder. "Having been through it ourselves, we know that without it, this child would pass," said Alison Rockett Frase, founder of Joshua Frase Foundation.

Wilson, like Alison's late son Joshua for whom the foundation is named, was born with myotubular myopathy, which causes very weak muscles, the patient is unable to eat without a feeding tube and requires a ventilator to breathe.

In Ecuador, the healthcare system cannot provide a portable ventilator for parents to take their child home to live out their life. "That means that his family can either chose to keep him alive and institutionalized or bring him home to perish unless they can find a way to pay for or acquire a home ventilator on their own," explained Frase.

Desperate to bring Wilson home, his family reached out to CNM Together Strong!, the association that helps families with centronuclear myopathies in Germany. They connected with Alison and the Joshua Frase Foundation, known for managing a medical equipment exchange program in the U.S.

"The logistical challenges from one country to the next, from customs and language barriers, to the updating of obsolete equipment were all overcome to save Wilson's life," said Frase. "This story shows that the beauty of humanity knows no boundaries and can span three continents, even when the world has been turned upside down."

For Wilson's parents, the gift was more than just a medical machine. "This was not just a gift of breath, but a gift of life in the truest sense," said Andre Carlozama and Daniel Augalsaca. "The joy and elation of now being able to bring Wilson home is immeasurable."

Both the Joshua Frase Foundation and CNM-Together Strong! in Germany are hoping to help the family with additional medical expenses, including maintenance of the ventilator and for doctor care while he is at home. For donations, please visit http://www.pleasedonate.organd tag "for Willson".

"Although children born with this often-fatal disorder live on borrowed time, it is essential that every family be provided the opportunity to bring their child home to spend quality time outside institutional walls," said Frase. "Every donation will mean so much for this family."

About The Joshua Frase Foundation(JFF) is a 501C3 non-profit organization that was founded in 1996; a year after Paul and Alison's son was born with an ultra rare and fatal neuromuscular disorder. Without hesitation, the foundation began funding cutting-edge research in the area of regenerative medicine, gene therapy and genetics since 1997. JFF's mission is twofold: To find a cure or treatment for centronuclear and myotubular myopathies and to support families whose lives are affected by these disorders. Not only has JFF been able to fund groundbreaking science, pioneering into a curative treatment that has the potential to transform neuromuscular research; it has also built an international community of children and their parents. The foundation's efforts have spearheaded human clinical trials for gene therapy. For more information, please visit http://www.joshuafrase.org.

About ZNM Zusammen Stark! e.V.(CNM Together Strong!) is a self-help association for myotubular myopathy and other centronuclear myopathies (CNM = ZNM). We represent (as of October 2019) 159 individuals from 52 families with a CNM in Germany, the Netherlands and Austria. As a self-help organization our main goal is to connect those affected and their families and to support each other in our daily lives. This is mainly done by our yearly family conference, conference, webinars and our closed Facebook support group. We also actively invest on research to find a treatment for these conditions. For more information please visit https://www.znm-zusammenstark.org/en.

Media Contacts: Alison Rockett Frase, Joshua Frase Foundation904-567-3933 or [emailprotected]Liz Morgan, Liz Morgan PR 904-608-3823 or [emailprotected]

SOURCE Joshua Frase Foundation

http://www.joshuafrase.org

Read the original here:
Amid COVID 19 Crisis, Joshua Frase Foundation Leads Search Spanning Two Continents to Deliver Ventilator to Ailing Child in Ecuador - PRNewswire

Read More...

CRISPR Therapeutics to Participate in Upcoming Investor Conferences – GlobeNewswire

May 27th, 2020 11:49 am

ZUG, Switzerland and CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in June:

Jefferies Global Healthcare ConferenceDate:Tuesday, June 2, 2020Fireside chat: 1:30 p.m. ET

Goldman Sachs 41st Annual Global Healthcare ConferenceDate:Tuesday, June 9, 2020Fireside chat: 9:40 a.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website athttps://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

Investor Contact:Susan Kim+1 617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel EidesWCG on behalf of CRISPR+1 617-337-4167reides@wcgworld.com

The rest is here:
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Read More...

First American to Receive Placental Cell Treatment For COVID-19 is an Acclaimed Broadway Scenic Designer – Science Times

May 27th, 2020 11:48 am

Edward Pierce, 49, an acclaimed Broadway set designer for plays like Wicked spent five weeks in a medically induced coma after contracting COVID-19 and was treated at a hospital in Teaneck, New Jersey.

His condition slowly deteriorated due to organ failure, and there seemed to be little hope, so his wife agreed to use an untested method developed by an Israeli biotechnology firm. He made history as the first American to receive placental cells in around 15 parts of his body.

According to the Daily Mail, Pierce was off a ventilator and breathing on his own just within ten days of treatment. The treatment is said to be part of the Food and Drugs Administrations' 'compassionate use.'

Pierce first thought that he had the flu, so doctors only prescribed him medicines and told him to stay home. However, his condition continued to worsen, and then he was admitted to the hospital. Four days later, he was put on a ventilator.

At one point in his stay, doctors had to restart his heart after it stopped when he pulled out his breathing tube. Pierce told The Daily Beast that he felt scared at the time because he does not want to be not in control.

He remembered that doctors asked him to count backwards from 10 and her wife told him that she loves him, and he said it back to her. That was the last thing he remembered before waking up five weeks later.

A lot has happened in those times, including him having kidney failure and needing dialysis. Luckily, he did not have to have that. His wife began thinking of what life would be like if Pierce did not make it. She would receive updates from the hospital, sometimes the news was good, sometimes it was not so good.

According to Pixie, the doctors are running out of options to save her husband. So they ask her to authorize an as-yet-untested treatment that extracts stem cells from human placenta.

Read Also: 115 Healthy Babies have Been Born from Mothers Infected with COVID-19 In India

Pluristem Therapeutics, an Israeli company who pioneered the treatment said that 75% of COVID-19 patients had been taken off the ventilator, according to The Jerusalem Post. The FDA permitted the company to offer the treatment on a case-by-case basis to patients under 'compassionate use.'

Compassionate use is the use of a new unapproved treatment for patients who are seriously ill and has not shown any improvements after every other option has been exhausted.

The proposed treatment includes using cells from the placenta or the intramuscular administration of the company's PLX-PAD, which is used for severe pneumonia caused by COVID-19 and preventing the deterioration of patients towards ARDS and sepsis.

Within ten days, Pierce was taken off a ventilator and started to breathe on his own. Gradually, doctors weaned him off of sedatives, and three days after he woke up, his breathing tubes, feeding tubes, and catheters were all removed.

Finally, on May 1, he was discharged from the hospital after nearly seven weeks of treatment. He was then sent to rehabilitation to rebuild his muscles and regain strength.

Read More: CDC Emphasized COVID-19 Not Easily Spread By Touching Surfaces or Objects

See the original post here:
First American to Receive Placental Cell Treatment For COVID-19 is an Acclaimed Broadway Scenic Designer - Science Times

Read More...

Predicting drug responses using pancreatic cancer organoids and multimodal plate imaging on SelectScience – SelectScience

May 27th, 2020 11:47 am

Pancreatic cancer is a deadly malignancy with few treatment models. Monolayer cell culture has failed to predict patient drug responses in the past. In response to this, a patient-derived organoid (PDO) methodology has been developed that enables the generation of models, from both surgically resected material and biopsies, with a success rate of 75-80%. These cultures enable the molecular dissection of treatment responses and resistance.

Here, Dannielle Engle and Christian Oberdanner will discuss the use of the Tecan SparkCyto to evaluate drug responses in PDO models. In short, PDO models were plated in a 384-well format, allowed to reform, and treated with compounds. The dose-responses of PDO models were compared to several agents using both CellTiter-Glo (Promega) to measure ATP levels, as well as the automated confluence measurement. This methodology provided the same endpoint analyses previously relied upon, plus the dynamic evaluation of changes to cell morphology and confluence. Confluence measurements were found to be comparable to ATP levels. Given the diversity observed amongst pancreatic cancer patients and the PDO models, dynamic measurements provide additional flexibility and information for precision medicine approaches.

Key learning objectives:

Who should attend:

Read the original:
Predicting drug responses using pancreatic cancer organoids and multimodal plate imaging on SelectScience - SelectScience

Read More...

CQuentia joins American Heart Association’s Center for Health Technology & Innovation Innovators’ Network with a focus on Precision Medicine -…

May 27th, 2020 11:47 am

FORT WORTH, Texas, May 27, 2020 /PRNewswire/ --CQuentia joinsthe American Heart Association Center for Health Technology and Innovation (the Center) Innovators' Network, which is focused on building and fostering health technologies and relationships in pursuit of innovative and scalable solutions across the healthcare market.

The Center's Innovators' Network helps its members align and integrate their technology with the Association's science-based health management plans, called CarePlans, to encourage development and adoption of digital healthcare solutions.

CQuentia is a next-generation sequencing FDA CLIA laboratory and data service that brings a comprehensive precision medicine platform to the Association's Innovators' Network. When integrated with the American Heart Association CarePlans, CQuentia combines advanced genomics including pharmacogenomics testing and molecular genetic pathology testing to deliver reliable, accurate and actionable genetic and molecular information in concert with leading science and technology. Providers, hospitals and payers are now actively seeking the means to customize care of their patients based on this type of individualized data.

"What separates CQuentia from other genetic testing laboratories is our platform-agnostic approach to deliver solutions and our ability to create client specific reports and alerts that are personalized to target disease state and comorbidities," said Alan Meeker, CQuentia CEO.

This endeavor aims to couple the knowledge gained from CQuentia's genomic testing to drive better personal adherence and control using the Association's CarePlans and health content.

"It's incredibly encouraging to see CQuentia leveraging best-in-class science from the American Heart Association with the aim of improving health education and health engagement," said Patrick Wayte, senior vice president of the American Heart Association Center for Health Technology and Innovation.

About CQuentia CQuentia is a privately-held molecular testing and laboratory company positioned to provide doctors, governments and employers with rapid, reliable results; enabling them to make informed clinical and population health decisions on how to provide the world with the most appropriate restorative care and infection prevention guidance.

For more information, please visit http://www.cquentia.com/covidtesting

SOURCE CQuentia

http://www.cquentia.com/

Read more:
CQuentia joins American Heart Association's Center for Health Technology & Innovation Innovators' Network with a focus on Precision Medicine -...

Read More...

Biobanks Market – Rising need for replacement organs and the steady advancement in the replacement drive growth of market – BioSpace

May 27th, 2020 11:47 am

Biobanks are essentially repositories for storing biological substances derived from humans, which may include organs, bio-specimens, plasma, saliva, and blood. With a vast rise in the number of organ replacement surgeries globally and significant advancements made in the fields of transfusion and replacement technologies, the role of the biobanks market has become more concrete in the healthcare sector in recent years.

The global biobanks market has witnessed expansion at a significant pace in the recent years owing to the vast rise in prevalence of a number of chronic diseases and the increased demand for personal medicine. The massive rise in incidence rate of conditions such as diabetes, cancer, neurovascular diseases, cardiovascular diseases, and respiratory diseases has compelled government bodies to take stronger actions in terms of investments in biobanks and increasing awareness about them. The global market for biobanks works in coherence with these efforts by adding pace to the process of drug discovery and the treatment of chronic diseases that are caused by activities such as smoking, consumption of alcohol, obesity, and unhealthy lifestyles.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2321

Heavy investment by a proactive government has boosted the North America biobanks market to the leading position in the global biobanks market, followed closely by Europe. Both regions are home to several bioscience companies and host a large number of drug discovery and research activities. Asia Pacific still remains the region with the most promising growth potential as the region shown high promise owing to an increase in investments from both government and non-government organizations, along with a large and increasingly affluent population base that is gaining awareness about the market.

Global Biobanks Market: Overview

The global biobanks market owes its conception to the rising need for replacement organs and the steady advancement in the replacement and transfusion technologies regarding a number of bodily substances. Though the technology and need to store organs and other bio-entities had been available for a long time, the global biobanks market took on a more important role in the healthcare sector following the increasing research in genomics. In the new millennium, the development of the personalized medicine field has been the vital driver for the global biobanks market. The likely advancement of the latter, thanks to helpful government regulations, is likely to make the crucial difference for the global biobanks market in the near future.

The steady technological advancement in the healthcare sector in the last few decades has now led to a scenario where the full potential of biobanks can be harnessed. As a result, the global biobanks market is projected to exhibit steady growth over the coming years.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=2321&ltype=S

Global Biobanks Market: Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2321

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market include BioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Continue reading here:
Biobanks Market - Rising need for replacement organs and the steady advancement in the replacement drive growth of market - BioSpace

Read More...

insideHPC Special Report: HPC and AI for the Era of Genomics – insideHPC

May 27th, 2020 11:47 am

This special report sponsored by Dell Technologies, takes a deep dive into HPC and AI for life sciences in the era of genomics. 2020 will be remembered for the outbreak of the Novel Coronavirus or COVID-19. While infection rates are growing exponentially, the race is on to find a treatment, vaccine, or cure. Governments and private organizations are teaming together to understand the basic biology of the virus, its genetic code, to find what can stop it.

Significant amounts of computing power are aimed at this problem, including using the most powerful high performance computing (HPC) systems in the world today. Finding a cure or eliminating COVID-19 will not only benefit the worldwide population, but will also be the foundation for tackling the next pandemic, which some scientists say will happen in the not too distant future.

This technology guide, insideHPC Special Report: HPC and AI for the Era of Genomics, highlights a lineup of Ready Solutions created by Dell Technologies which are highly optimized and tuned hardware and software stacks for a variety of industries. The Ready Solutions for HPC Life Sciences have been designed to speed time to production, improve performance with purpose-built solutions, and scale easier with modular building blocks for capacity and performance.

Introduction

2020 will be remembered for the outbreak of the Novel Coronavirus or COVID-19. While infection rates are growing exponentially, the race is on to find a treatment, vaccine, or cure. Governments and private organizations are teaming together to understand the basic biology of the virus, its genetic code, to find what can stop it. Significant amounts of computing power are aimed at this problem, including using the most powerful high performance computing (HPC) systems in the world today.[1] Finding a cure or eliminating COVID-19 will not only benefit the worldwide population, but will also be the foundation for tackling the next pandemic, which some scientists say will happen in the not too distant future.[2]

Artificial Intelligence (AI)

Slav Petrovski, Head of Genome Analytics and Informatics at AstraZenecas Centre for Genomics Research (CGR) explains that there is a wide range of uses for AI within this field. He says that the approximately three billion base pairs that make up the human genome can be analyzed through AI to find genetic variations. The next step is to determine the level of confidence to be placed in the differing data to decide if it represents a biological genetic variant.

AI is being combined with traditional HPC simulations to predict more accurate results. Based on previous completed computations, an algorithm is able to determine what the next input or result could be. For example, if protein A shows a possible affinity to kill the Coronavirus, then does protein B (or others) have a better chance or could be more effective?

There are a number AI uses within genomics research that can identify and facilitate drug target interaction. By combining analytical and automated processes with the ongoing study of genomics, a more complete understanding of this field will progress. AI can lead to greater insights into the patterns and anomalies in the data, where humans may not see the correlations at first. By using machine and deep learning techniques, new and more effective medicines can get to patients faster and will be better targeted to fight diseases.

Produvia, a research company, has identified five areas where AI will benefit genomic research moving forward:

Precision Medicine

While AI can benefit genomic research, the end goal is to create treatments that specifically attack the genetic code of the infection or disease, and to create treatments that are tailored to an individuals genetic makeup. To do this requires significant data, computing power, and collaborations that combine expertise from many disciplines.

With a combination of faster and more accurate genomic sequencing with faster computer systems and new algorithms, the movement of discovering what medicine will work best on individual pathogens and patients has moved from research institutions to bedside doctors. Physicians and other healthcare providers now have better, faster and more accurate tools and data to determine optimal treatment plans based on more data. This is especially true for pediatric cancer patients.

Personalized or precision medicine holds the key to innovative approaches to manage diseases on an individual level. Various decisions regarding the management of healthcare to each pathogen and/or individual is customized, based on the knowledge of the genetic or cellular information. Diagnosis of diseases, and the resulting treatments can be tailored for each person. However, a number of challenges exist as this scientific field moves forward, such as regulatory oversight, intellectual property rights and patient privacy.

Worldwide, many countries are dedicating resources and efforts to learn more about genomics and how to apply this knowledge to personalizing medicine. Figure 1 shows the worldwide effort to bring precision medicine to those in need. Figure 2 shows how the cost of decoding a human genome has come down, even faster than Moores Law.

Over the next few weeks we will explore these topics surrounding HPC and AI for life sciences in the era of genomics:

Download the complete insideHPC Special Report: HPC and AI for the Era of Genomics, courtesy of Dell Technologies.

[1] COVID-19 HPC Consortium

[2] Scientists in race to protect humanity from future pandemics

See more here:
insideHPC Special Report: HPC and AI for the Era of Genomics - insideHPC

Read More...

AI & Medicine An Expert in AI-aided Drug Discovery and Medical Applications – Bio-IT World

May 27th, 2020 11:47 am

NEW YORK, NY, UNITED STATES - May 27, 2020 - Recently founded, the New York-based company AI & Medicine is an expert in the field of AI-Powered drug discovery, personalized healthcare and various medical applications. Having launched a unique AI-aided drug discovery platform last month, this company grows quickly with concerted support from many talented researchers and scientists. It offers drug R & D solutions from the perspective of AI for medical institutions and pharmaceutical enterprises worldwide.

AI is transforming the practice of medicine. Owing to its ability to identify meaningful relationships in raw data, AI can be used in multiple medical scenarios. For example, it helps doctors diagnose patients more accurately, make predictions about patients future health, and even recommend better treatments. It is quite fair to say that AI can be applied in nearly every field of medicine.

AI & Medicine can help apply machine learning to solve the following four concrete problems:

Drug Research and Development

Through big data analysis and other technical means, the AI-powered drug discovery platform offered by AI & Medicine can quickly and accurately mine data and select the appropriate lead compounds. Especially in contrast with traditional methods, AI can help save a great deal of time, cost, and energy in a range of steps regarding drug discovery, including drug target discovery, candidate drug discovery, prediction of drug crystal form, ADMET prediction, design and optimization of clinical trials, pharmacovigilance, etc.

Medical Translation

The company's AI technology has accumulated a lot in big data, natural semantic analysis, machine learning and deep neural network. A team of scientist with well-equipped knowledge in medical field is capable of optimizing the medical translation system, offering multilingual translation and at the same time ensure the standard and preciseness of medical translation.

Medical Imaging

AI technology is applied in medical imaging area through imaging analysis and surgical simulation.

Main AI methods include image segmentation, feature extraction, quantitative analysis, comparative analysis, etc. AI is increasingly helping to reveal hidden insights into clinical decision-making, connect patients with resources for self-management, and extract meaning from previously inaccessible, unstructured data assets.

Medical Therapy and Research

The company's Intelligent Inquiry and Guidance platform uses the medical AI engine to accurately identify and match the needs of both doctors and patients. Advanced analytics and machine learning techniques are being used concurrently to help uncover critical insights and best practices from the billions of data elements associated with robotic-assisted surgery. Moreover, AI is also helpful in electronic medical record establishment, literature reading and information extraction.

To learn more information about AI & Medicine's capability in AI-powered drug discovery and medical application, please visit:https://aimed.protheragen.com/solutions.html.

About AI & Medicine

Missioned to helping fulfill the specific drug R&D requirements in the industry, AI & Medicine successfully develops an AI-powered drug discovery platform for medical institutions and pharmaceutical enterprises across the globe, offering a broad and integrated portfolio of medical and scientific solutions in areas like drug R&D, medical translation, medical imaging, medical therapy and research system, and more.

Here is the original post:
AI & Medicine An Expert in AI-aided Drug Discovery and Medical Applications - Bio-IT World

Read More...

Insights on the Worldwide Next-generation Sequencing Industry to 2025 – Featuring Illumina, BGI Group & Perkinelmer Among Others – GlobeNewswire

May 27th, 2020 11:47 am

Dublin, May 27, 2020 (GLOBE NEWSWIRE) -- The "Global Next-generation Sequencing Market By Product (Consumables, Platforms and Services), By Technology (Sequencing by Synthesis, Pyrosequencing, and Other Technologies), By End User, By Application, By Region, Competition, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Next-Generation Sequencing Market is projected to grow at a CAGR of close to 20% to reach USD24 billion during the forecast period.

Enhancing regulatory framework for next-generation sequencing based tests for diagnostics is the key factor for the growth of the Global Next-Generation Sequencing Market during the forecast period. Moreover, advancements in next-generation sequencing coupled with reduction in the price of NGS platforms are some other major factors that are anticipated to bolster the growth of the Global Next-Generation Sequencing Market over the coming years. However, some of the factors that might act as major impediments to the growth of the Global Next-Generation Sequencing Market includes concerns pertaining to the standards of NGS based diagnostics.

The Global Next-Generation Sequencing Market is segmented based on product, technology, end-user, application, region and company. Based on technology, the market can be segmented into sequencing by synthesis, ion semiconductor sequencing, sequencing by ligation, pyrosequencing, single molecule real time sequencing and other technologies. Among them, the sequencing by synthesis (SBS) segment dominated the market until 2019 and is projected to grow with a healthy CAGR over the forecast period due to development of new and advanced NGS platforms along with the rising demand for Illumina's systems as it uses the SBS technology.

Major players operating in the Global Next-Generation Sequencing Market include Illumina, Inc., Thermo Fisher Scientific, Inc, BGI Group, Agilent Technologies, Inc., Qiagen N.V., Hoffmann-La Roche AG, 10x Genomics, Oxford Nanopore Technologies, Takara Bio and others.

Objective of the Study:

The author performed both primary as well as exhaustive secondary research for this study. Initially, researchers sourced a list of service providers across the globe. Subsequently, they conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, researchers could include the service providers which could not be identified due to the limitations of secondary research. The author analyzed new services, distribution channels and presence of all major players across the globe.

The author calculated the market size of the Global Next-Generation Sequencing Market by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. Researchers sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Next-generation Sequencing (NGS) Market Outlook5.1. Market End User & Forecast5.1.1. By Value5.2. Market Share & Forecast5.2.1. By Product (Consumables, Platforms and Services)5.2.1.1. By Consumables (Sample preparation consumables and Other Consumables)5.2.1.2. By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms)5.2.1.3. By Services (Sequencing Services and Data management services)5.2.2. By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing and Other Technologies)5.2.3. By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others)5.2.4. By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Other Applications)5.2.5. By Region5.2.6. By Company (2019)5.2.6.1. By NGS Platform

6. North America Next-generation Sequencing (NGS) Market Outlook6.1. Market End User & Forecast6.2. Market Share & Forecast6.3. North America: Country Analysis

7. Europe Next-generation Sequencing (NGS) Market Outlook7.1. Market End User & Forecast7.2. Market Share & Forecast7.3. Europe: Country Analysis

8. Asia-Pacific Next-generation Sequencing (NGS) Market Outlook8.1. Market End User & Forecast8.2. Market Share & Forecast8.3. Asia-Pacific: Country Analysis

9. Middle East and Africa Next-generation Sequencing (NGS) Market Outlook9.1. Market End User & Forecast9.2. Market Share & Forecast9.3. MEA: Country Analysis

10. South America Next-generation Sequencing (NGS) Market Outlook10.1. Market End User & Forecast10.2. Market Share & Forecast10.3. South America: Country Analysis

11. Market Dynamics11.1. Drivers11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape (NGS Platform Providers)13.1. Competition Outlook13.2. Company Profiles13.2.1. Illumina, Inc.13.2.2. Thermo Fisher Scientific, Inc13.2.3. BGI Group13.2.4. Perkinelmer13.2.5. Agilent Technologies, Inc.13.2.6. Qiagen N.V.13.2.7. F. Hoffmann-La Roche AG13.2.8. 10x Genomics13.2.9. Oxford Nanopore Technologies13.2.10. Takara Bio

14. Strategic Recommendations

15. About Us & Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/2rcwyi

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the rest here:
Insights on the Worldwide Next-generation Sequencing Industry to 2025 - Featuring Illumina, BGI Group & Perkinelmer Among Others - GlobeNewswire

Read More...

Treating rebound headaches with early preventative meds best choice, study finds – Henry Herald

May 27th, 2020 11:46 am

Your head is pounding yet again. You grab another round of pain meds, only to find they no longer work.

You may be suffering from a MOH -- a medication overuse headache -- brought on when the very medications you relied on for relief suddenly become the enemy.

Some 60 million people around the world suffer from headaches brought on by the overuse of medication. It typically happens to people who suffer from migraines, cluster headaches or tension-type headaches who are using medications that don't work.

When the pain doesn't ease, they take another pill, thus setting the scene for what is often known as a "rebound" headache.

Instead of a headache that might call for pain medications two or three times a week, people with MOH now have a headache nearly every day, typically upon awakening. For many, this is a new level of chronic pain -- and there's no miracle pill to fix it.

Is cold turkey best?

Withdrawal therapy is currently the only treatment for this disorder, sometimes combined with physical or behavioral therapy and preventative medicine treatments, sometimes called "bridge therapies."

Those preventative medicine treatments include anticonvulsants, antidepressants, beta blockers and calcium channel blockers that might help control withdrawal pain without risking medication overuse headaches. At times a patient may be given injections of Botox or antibodies designed to thwart migraines.

But not always. In Denmark, for example, guidelines suggest a complete withdrawal, totally discontinuing any pain medications for two months before other options are provided.

"Withdrawal has been recommended for years in European Guidelines, including the most recent published from May 2020," said Dr. Rigmor Jensen, a professor of headache and neurological pain who directs the Danish Headache Center at the University of Copenhagen, and is lead author on a new study to see if those recommendations were right.

In fact, doctors have long debated whether any preventative treatments were necessary to help patients wean off medications -- believing the vast majority of patients did just as well with a cold-turkey approach.

After all, most withdrawal headaches tend to improve in less than a week, although some patients did need to be hospitalized, especially if they were withdrawing from opioids.

"In placebo-controlled studies for preventive treatment, the effect has been modest," Jensen said. "So, we decided to compare these treatment strategies directly in this study to clarify the question."

Jensen and his coauthors hypothesized that withdrawal alone, or withdrawal with preventatives, would work better in reducing overall headache days per month than a preventative approach.

However, the results of their study, published Tuesday in the journal JAMA Neurology, surprised the authors.

While all three treatments were effective in reducing MOH, the largest reductions in headache and migraine days, days with short-term medication use and days with headache pain intensity were seen in the withdrawal plus preventive medicine group.

In addition, people who withdrew from meds with the help of preventatives had a significantly higher chance of being cured of their medication overuse headaches than patients who used preventatives or withdrawal alone.

"We were surprised of the study results and the excellent adherence to the treatment," Jensen said. "We now recommend withdrawal and early start of preventive treatment."

"Having good medical evidence to support the common practice of both stopping the offending agent or agents, and starting a patient on prevention medication right away, will clear up some of the controversy and confusion," said Dr. Rachel Colman, director of the Low-Pressure Headache Program at the Icahn School of Medicine at Mount Sinai in New York.

Doctors should use this study to "provide patients with guidance, support and hopefully relief from a disabling condition," said Coleman, who was not involved in the study and is a member of the National Headache Foundation Health Care Professionals Leadership Council.

Coleman also pointed out that due to timing of the trial, the study did not include the newest options for prevention, called CGRP monoclonal antibodies, that have become available in the last two years. These are a new class of medication created specifically for migraine headaches.

However, Jensen said that going "cold-turkey" may still have some benefits for patients, especially those with less severe rebound headaches. Prior studies have found that when patients feel their actions exert control over their headaches, it can help them from overusing medications in the future.

"Patients who withdraw completely experience that a headache can disappear by itself, and that experience is important when talking about preventing relapse into a new medication overuse," Jensen said.

What causes a MOH?

Just how much pain medication will cause a rebound headache depends on the medicine.

According to the American Migraine Foundation, over-the-counter pain relievers, such as aspirin, acetaminophen, ibuprofen, naproxen and indomethacin, can cause MOH when used 15 or more days per month.

It will only take about 10 days of use for medications that combine caffeine, aspirin and acetaminophen to contribute to a MOH. Ten days is also the max for tryptamine- and ergotamine-based drugs often prescribed for migraines, as well as any of the opiates: oxycodone, tramadol, butorphanol, morphine, codeine or hydrocodone.

Just 200 milligrams of coffee will also trigger a medication overdose headache. That's just one cup of coffee combined with a coke and a plain chocolate bar.

It's not just pain in the head either. Often MOH can cause memory issues, difficulty concentrating, depression, anxiety, irritability, restlessness and nausea.

Now, more than ever, the world needs trustworthy reportingbut good journalism isnt free.Please support us by subscribing or making a contribution today.

Here is the original post:
Treating rebound headaches with early preventative meds best choice, study finds - Henry Herald

Read More...

Leading Thrombosis Specialists Issue Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients…

May 27th, 2020 11:46 am

CHAPEL HILL, N.C., May 27, 2020 /PRNewswire/ --Leading thrombosis specialists from the International Society on Thrombosis and Haemostasis(ISTH) and World Thrombosis Day(WTD) Steering Committee recommend administering either standard preventative or larger doses of heparin (blood thinning medicine) to combat excessive clotting in all hospitalized COVID-19 patients from the time of hospital admission, unless they have contraindications to those medications.

This proposed "universal" intervention strategy is a change from the current practice of using only preventative levels of such medications after individual venous thromboembolism (VTE) risk assessment of hospitalized patients.

The recommendations are published in a new paper, titled "Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19," published on May 27, 2020 in the Journal of Thrombosis and Haemostasis (JTH). The peer-reviewed paper outlines new practical guidance on the prevention and treatment of VTE in hospitalized patients with COVID-19.

The recommendations were developed by a multidisciplinary panel of thrombosis experts as a response to widespread clinical reports of unusual, difficult-to-control clotting in COVID-19 patients."Early reports suggest COVID-19 is one of the most thrombotic disease states we've ever seen," said lead author Alex Spyropoulos, M.D., member of the WTD Steering Committee. Co-authors include leading scientists from six countries (see below for list).

In issuing new guidance, the authors analyzed reports from colleagues around the world who observed that patients hospitalized with COVID-19 had a high incidence of thrombotic events (blood clots). The authors caution that the data are based on anecdotal reporting rather than rigorous scientific research. Thus, guidance may change as data improves, though the scientists generally agree the recommendations are sufficiently supported to be adopted into practice.

"We consider this a living document," Spyropoulos said. "This is a very fast-moving target. The data are important, but even more important is our need to take care of patients now. We see this correlation with clotting, and we must act."

"In the United Kingdom, we are seeing high rates of blood clots in our patients even as they receive standard doses of blood thinners," said Professor Beverley Hunt, M.D., OBE, WTD Steering Committee Chair. "These patients seem to need larger doses than other sick patients. We need to know the best doses going forward."

Additional research is in development in the UK at this time, via a clinical trial named REMAP-CAP, to capture the response of COVID-19 patients to different dosing levels of blood thinning medications. This will provide more guidance for healthcare professionals globally, Hunt said.

While much remains unknown, the authors have concluded that patients with severe cases of COVID-19 develop VTE at a much higher rate than severely ill patients in general. VTE is a condition in which blood clots form (most often) in the deep veins of the leg (known as deep vein thrombosis or DVT), and can travel in the circulation to lodge in the lungs (known as pulmonary embolism, or PE). The development of this condition in hospitalized COVID-19 patients results in a much higher risk of death, particularly in patients with preexisting cardiovascular disease.

COVID-19 patients in the intensive care unit (ICU) are three to six times more likely to experience DVT than a patient in ICU for some other reason, such as congestive heart failure.

The authors also noted that the clots exhibit particular characteristics. Clots that lead to cardiac events, such as heart attacks and strokes, are typically large. In COVID-19 patients, however, in addition to the usual large clots seen in these patients, smaller clots (microthrombi) are also present in the lungs.

Clinicians have not identified a specific cause of blood clotting in COVID-19 patients, but believe it is due to the extreme immune response to COVID-19 that causes very sticky blood. Early research on COVID-19 found that blood clots are playing a role in a significant percentage of all COVID-19 deaths in the United States. Patients in the United States, however, are not routinely given blood thinners, in contrast to patients in the United Kingdom.

For more information on the paper, "Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19," visit https://onlinelibrary.wiley.com/doi/abs/10.111/jth.14929.

Co-authors include: Jerrold H. Levy (United States), Walter Ageno (Italy), Jean Marie Connors (United States), Beverley J. Hunt (United Kingdom), Toshiaki Iba (Japan), Marcel Levi (United Kingdom), Charles Marc Samama (France), Jecko Thachil (United Kingdom), Dimitrios Giannis (United States), and James D. Douketis (Canada)

SOURCE International Society on Thrombosis and Haemostasis

http://www.isth.org

Read more here:
Leading Thrombosis Specialists Issue Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients...

Read More...

Letter to the editor: Can they hate Trump any more? – TribLIVE

May 27th, 2020 11:46 am

You are solely responsible for your comments and by using TribLive.com you agree to ourTerms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sentvia e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.

Read more here:
Letter to the editor: Can they hate Trump any more? - TribLIVE

Read More...

Drug Touted by Trump as COVID-19 Treatment Tied to Increased Risk of Death: Study – The New York Times

May 27th, 2020 11:46 am

(Reuters) - The anti-malarial drug hydroxychloroquine, which U.S. President Donald Trump says he has been taking and has urged others to use, was tied to an increased risk of death in hospitalized COVID-19 patients, a large study published on Friday showed.

In the study https://www.thelancet.com/lancet/article/s0140673620311806 that looked at more than 96,000 people hospitalized with COVID-19, the respiratory disease caused by the novel coronavirus, those treated with hydroxychloroquine or the related chloroquine had higher risk of death and heart rhythm problems than patients who were not given the medicines.

The study, published in the Lancet medical journal, showed no benefit for coronavirus patients taking the drugs.

Demand for the decades-old hydroxychloroquine has surged as Trump repeatedly promoted its use against the coronavirus, urging people to try it. "What have you got to lose?" he asked.

Trump said this week he has been taking hydroxychloroquine as a preventative medicine despite a lack of scientific evidence.

The Lancet study authors suggested that hydroxychloroquine and chloroquine should not be used to treat COVID-19 outside of clinical trials until studies confirm their safety and efficacy in such patients.

There is a frantic search for drugs to treat COVID-19 at the same time that multiple research teams pursue a safe and effective vaccine to combat a pathogen that has killed more than 335,000 people worldwide and sickened millions more.

The U.S. Food and Drug Administration has allowed healthcare providers to use the drugs for COVID-19 through an emergency-use authorization, but has not approved them to treat it.

Dr. Mandeep Mehra, one of the study's authors, said the research shows that the FDA should withdraw that authorization.

"That will help move this towards more, stronger evidence because it will then force the use of these drugs only in the setting of control trials," Mehra said in an interview. "That would be an extremely wise decision."

The FDA has said that, for safety reasons, hydroxychloroquine should be used only for hospitalized COVID-19 patients or those in clinical trials. The drug has been tied to dangerous heart rhythm problems.

The Lancet study looked at data from 671 hospitals where 14,888 patients were given either hydroxychloroquine or chloroquine, with or without an antibiotic, and 81,144 patients were not given such treatments.

Both drugs have shown evidence of effectiveness against the coronavirus in a laboratory setting, but studies in patients had proven inconclusive. Several small studies in Europe and China spurred interest in using hydroxychloroquine against COVID-19, but were criticized for lacking scientific rigor.

Several more recent studies have not shown the drug to be an effective COVID-19 treatment. Last week, two studies published in the medical journal BMJ showed that patients given hydroxychloroquine did not improve significantly over those who were not.

Hydroxychloroquine is used to treat lupus and rheumatoid arthritis as well as malaria.

Hospitalized patients tend to have a more severe version of COVID-19. Some proponents of the drugs for COVID-19 argue that they may need to be administered at an earlier stage to be effective.

There are ongoing randomized, controlled clinical trials to study the drug's effectiveness in preventing infection by the coronavirus as well as treating mild to moderate COVID-19. Some of those may yield results within weeks.

(Reporting by Ankur Banerjee and Manas Mishra in Bengaluru and Michael Erman in New York; Editing by Saumyadeb Chakrabarty, Bill Berkrot, Jonathan Oatis and Will Dunham)

Original post:
Drug Touted by Trump as COVID-19 Treatment Tied to Increased Risk of Death: Study - The New York Times

Read More...

Drug Touted by Trump as COVID-19 Treatment Tied to Increased Death Risk, Study Finds – Voice of America

May 27th, 2020 11:46 am

WASHINGTON - Malaria drug hydroxychloroquine, which U.S. President Donald Trump says he has been taking, is tied to increased risk of death in COVID-19 patients, according to a study published in medical journal Lancet.The study which observed over 96,000 people hospitalized with COVID-19, showed that people treated with the drug, or the closely related drug chloroquine, had higher risk of death when compared to those who had not been given the medicine.Demand for hydroxychloroquine, a drug approved decades ago, surged after Trump touted its use as a coronavirus treatment in early April. Earlier this week, he surprised the world by admitting he was taking the pill as a preventative medicine.The Lancet study authors suggested these treatment regimens should not be used to treat COVID-19 outside of clinical trials until results from clinical trials are available to confirm the safety and efficacy of these medications for COVID-19 patients. The authors said they could not confirm if taking the drug resulted in any benefit in coronavirus patients.Weeks ago, Trump had promoted the drug as a potential treatment based on a positive report about its use against the virus, but subsequent studies found that it was not helpful. The U.S. Food and Drug Administration in April issued a warning about its use.The Lancet study looked at data from 671 hospitals, where 14,888 patients were given either hydroxychloroquine or chloroquine, with or without the antibiotic macrolide, and 81,144 patients were not on any of the treatment regimens.

See the original post here:
Drug Touted by Trump as COVID-19 Treatment Tied to Increased Death Risk, Study Finds - Voice of America

Read More...

In Online Covid-19 Videos, A Mix of Science and Conjecture – Undark Magazine

May 27th, 2020 11:46 am

In mid-March, filmmaker Robert Cibis at the time best known for a 93-minute documentary about a master piano tuner uploaded a short interview with the German physician and socialist politician Wolfgang Wodarg to YouTube. In the video, Wodarg alleges that the Covid-19 pandemic is a hype drummed up by sensationalist virologists and spread by scientists who want to be important in politics because they need money for their institutions.

Within days, the Wodarg interview had been viewed hundreds of thousands of times (the total now tops 2 million on YouTube), and Cibis and his production company, Oval Media, started raising money for a documentary, called Corona.film. Featuring Wodarg and other scientists, the film is billed as an exploration of the coronavirus and its media influence. On the crowdfunding platform IndieGoGo, hundreds of people have chipped in donations totaling about $105,000 to keep the project going.

The trailer for Corona.film features a high-profile scientist alongside Wodarg: John Ioannidis, a professor of medicine, epidemiology, and population health at Stanford University. Ioannidis co-directs a major center at Stanford that pushes for more rigorous biomedical research; a 2010 Atlantic magazine profile argued that he may be one of the most influential scientists alive. During the current pandemic, while praising public health officials, Ioannidis has criticized the lockdowns as based on too-thin evidence a position that has earned him fierce, albeit respectful,criticismfrom many colleagues. (The pushback intensified this week over a new Ioannidis analysis that many of his colleaguespilloriedonline, with somecitingoversights and inconsistencies in the data included in the study.)

In the teaser, after Wodarg calls for a closer look at the coronavirus epidemic that we allegedly are having right now, Ioannidis explains that, while elements of the pandemic are serious, he thinks there is a very high chance we are exaggerating the risk of the novel coronavirus.

Asked about Corona.film, Ioannidis told Undark he had never heard of it.

As SARS-CoV-2, the coronavirus that causes Covid-19, has swept across the globe, killing hundreds of thousands of people and overwhelming medical systems in the United States, Italy, Ecuador, and other countries, the pandemic has also nurtured a rich ecosystem of digital backlash. To be sure, some people have raised serious and reasonable questions about whether global lockdowns are worth the economic and social cost, which could be especially devastating in some developing countries. But many more hew to unfounded theories that the pandemic is, for example, caused by 5G towers; that it emerged from a lab in China; or that it is the result of a conspiracy by global leaders and plutocrats, especially billionaire Bill Gates.

The story of how footage of the Stanford professor ended up in Corona.film is just one example of how, amid the confusion of the pandemic, the views of serious scientific dissenters are being swiftly metabolized by a sprawling world of ideologues and conspiracy theorists. The tale runs through an independent film distribution company, and it involves a New York-based filmmaking team that has found millions of viewers online through an interview project that features a rich mix of marginal perspectives and pedigreed academics, Ioannidis most prominent among them.

The scientists in the films are not conspiracy theorists, theyre not anti-vaxxers theyre not like us, says one of the filmmakers, John Kirby, who suggested, without citing specific evidence, that the pandemic has been engineered by a global elite seeking to expand itscontrol over the world. But they are incredibly eminent, respected people who are thankfully independent enough to raise a question.

Before the Covid-19 pandemic began, Kirby and his filmmaking partner, Libby Handros, were working on a documentary about the assassinations of the 1960s, including the 1963 murder of President John F. Kennedy, which some people have long-maintained was the result of a government conspiracy. Media coverage of the coronavirus, Kirby told Undark, sounded similar to how they see coverage of the Kennedy assassination: an obfuscation of a deeper, more frightening truth. We sensed a rollout, a very large rollout, Kirby said.

We just want to keep bringing out alternative, sometimes overlapping opinions from experts and journalists.

The filmmakers approached Ioannidis for an interview, producing an hourlong video in which he analyzes the Covid-19 response, speaking in detail about the difficulty of pinning down precise data about a fast-moving pandemic. With the Ioannidis interview in hand, Handros and Kirby pitched the series to Journeyman Pictures, an independent film distributor in the United Kingdom that works with hundreds of documentaries each year.

We saw it as something interesting which would give, exactly as we called it, Perspectives on the Pandemic a broader perspective than we were getting from the increasingly controlled and narrow line being fed to us by the mass media every day, said Mark Stucke, the founder and managing director of Journeyman Pictures.

Journeyman signed Handros and Kirby up and began sharing the Ioannidis video with its 1.4 million YouTube subscribers. Off we went, Stucke said. And boom! It did go boom.

The interview soon picked up hundreds of thousands of views. Thousands also tuned into a conversation with David L. Katz, a physician, former Yale professor, and expert in preventative medicine who has drawn attention for a New York Times op-ed arguing that the negative effects of the lockdowns could outweigh the benefits.

Millions more people watched a viral interview with Knut Wittkowski, a former biostatistician at Rockefeller University who argues that the virus should be allowed to spread unchecked among healthy people until enough people become immune a strategy, widely criticized by experts, that has been partly adopted by the chief epidemiologist in Sweden.

Follow-up conversations with Wittkowski and Ioannidis, in which the latter described the results of his controversial study of Covid-19 prevalence in California, brought hundreds of thousands more views.

In a wide-ranging interview, Kirby and Handros spoke with Undark about the Kennedy assassination, Handros clashes with Donald Trump in the 1990s over a film she made, and Kirbys opposition to current vaccine policies, as well as his suspicion that Bill Gates is planning and manipulating the pandemic response. Most people are not ready to understand that this is not just sort of a public health crisis that governments are doing their best to respond to and maybe screwed up, Kirby said, without offering clear evidence. We just want to keep bringing out alternative, sometimes overlapping opinions from experts and journalists, he added, noting that they may start covering a range of topics. We want to ease people into some of the harder-to-appreciate stuff.

Some of the content in Perspectives on the Pandemic veers more directly into anti-government politics. In the first interview with Wittkowski, published in early April, the scientist said: Im not paid by the government, so Im entitled to actually do science. He also suggested that, left unchecked, the virus could exact a death toll of 10,000 in the U.S. and disappear on its own.

Today, the official U.S. death count is above 90,000, with cases rising in much of the country. In a phone conversation and follow-up emails, Wittkowski defended his projections, arguing that, while specific predictions may not bear out, he was correct to question lockdowns, and that the current death count was dramatically overstated. (There is growing evidence that it is actually an underestimate.) He claimed that the course of the pandemic was as predictable as the effects of gravity. Social distancing is a strategy for the government to reduce the democratic rights of the people, he wrote.

The idea that the Covid-19 pandemic is the result of a conspiracy is ludicrous.

Rockefeller University has publicly distanced itself from Wittkowski, explaining in a statement that comments about discouraging social distancing he has made do not represent the views of The Rockefeller University, its leadership, or its faculty. But his videos for Perspectives on the Pandemic have received widespread attention, including in the New York Post and The Epoch Times an outlet, analysts say, that has been instrumental in pushing the thus-far-unfounded claim that the SARS-CoV-2 virus originated in a Chinese lab and the American Institute for Economic Research, a right-leaning think-tank. Wittkowski has also appeared on an internet talk show hosted by Del Bigtree, a prominent anti-vaccination activist.

Earlier this month, YouTube removed one of Wittkowskis interviews for Perspectives on the Pandemic, citing unspecified violations of its policies. This week, YouTube removed Wittkowskis other interview, as well as the first, long, interview with Ioannidis.

According to YouTube, the Ioannidis video violated the platforms Covid-19 Medical Misinformation Policy, which, among other rules, states that YouTube doesnt allow content that spreads medical misinformation that contradicts the World Health Organization (WHO) or local health authorities medical information about Covid-19. A YouTube spokesperson did not respond to a request on Friday afternoon for specific details about how the Ioannidis interview had violated that policy.

Journeyman Pictures is asking YouTube for clarification regarding the decisions.

After watching the Ioannidis interviews, Cibis approached Journeyman about using the footage in his Covid-19 documentary. The distributor had worked with Oval Media on a previous documentary, also featuring Wodarg, that alleges corruption at the WHO. Stucke agreed, which is how Ioannidis ended up featuring prominently in a trailer for the film, alongside Wodarg, who has continued to argue, despite the mounting global death toll, that the pandemic is largely a fabrication.

Cibis told Undark that he had been surprised and a little frightened by the strong reactions to his original interview with Wodarg, acknowledging that it may have been just naive to publish the video without any research or context. But he rejected characterizations of Wodarg as a conspiracy theorist. His new film, he said, will have diverse perspectives although he added that he has concerns about using footage from one high-ranking Italian public health official who has warned that the virus is particularly dangerous, because Cibis feels it was unscientific and just fear-making.

Stucke, meanwhile, said that while he was aware that Handros and Kirby fit comfortably at the conspiratorial end of the world of journalism, he thought their project seemed sound, and that they were speaking with qualified sources. The Wittkowski interview, though, ultimately gave him pause. He said that if he had seen this interview first and as a standalone piece, rather than in the context of other interviews in the series, I would have probably thought twice about saying Yes, go for it. He admitted to knowing little about certain details of the Cibis project.

Some participating scientists, too, seemed surprised about the context in which their interviews were being presented. Asked whether he was aware of the conspiracy-oriented side to the Perspectives on the Pandemic project, Yale Universitys Katz replied No in an email, adding that the idea that the Covid-19 pandemic was the result of a conspiracy is ludicrous.

The interview was long-form, meaning I could speak my full views so it seemed a good venue, Katz wrote.

All that I really count on the production side to do, he added, is (a) not alter my views by editing them or taking them out of context; [and] (b) give me an audience.

Ioannidis said he was unaware that Journeyman had licensed footage of his interview to the German filmmakers. He also expressed surprise that there might be a conspiracy-oriented dimension to the Perspectives on the Pandemic series. I am clearly not aware of that, he said. Ive talked with John Kirby for two hours during these interviews. None of these questions arose.

People with different conflicts of interest, they will probably use ammunition from perspectives or data or science that has nothing to do with their agenda. It is a concern, Ioannidis said. I do share that concern, but its impossible to censor science, or to, lets say, factor every possible crazy perspective into account before you say, well, These are my data, and this is what I think about them.

But Leah Ceccarelli, a scholar of rhetoric and communication the University of Washington who studies scientific controversy, was skeptical about that line of argument.

Of course, the scientist wants to present the ethos of the disinterested searcher for truth, she said. As a scientist, Im just telling you the way that it is, and its not my job to think about the politics of this.

But that, Ceccarelli said, is totally naive.

Visit link:
In Online Covid-19 Videos, A Mix of Science and Conjecture - Undark Magazine

Read More...

First UK healthcare worker to enrol in COVID-19 prevention trial – PharmaTimes

May 27th, 2020 11:46 am

The first UK frontline NHS worker will today enrol in a new study designed to test the potential of hydroxychloroquine to prevent infection with novel coronavirus.

COPCOV is the largest multi-national interventional clinical study into the prevention of COVID-19 using hydroxychloroquine, which will involve around 40,000 healthcare workers.

The study has launched at Brighton and Sussex University Hospitals and the John Radcliffe Hospital in Oxford, which are the first of 20 UK hospitals set to participate.

Researchers hope to determine whether hydroxychloroquine/chloroquine can be used to effectively protect frontline medical staff, allowing them to undertake their vital roles more safely.

Accord Healthcare, a UK-based medicines manufacturer, has donated over two million tablets to enable this landmark trial to go ahead.

Based on the known pharmacology of hydroxychloroquine, coupled with the emerging knowledge surrounding SARS-CoV-2 viral replication and COVID-19 pathophysiology, we were very keen to test the effectiveness of this molecule in a preventative, rather than late-stage treatment setting, said Dr Anthony Grosso, VP & head of Scientific Affairs, Accord Europe & MENA.

A large-scale, prospective, randomised, double-blind clinical trial in a high-risk setting is the only way to robustly determine if this medicine can lessen or prevent human infection. Previous studies have not adequately tested this hypothesis; the results of COPCOV are therefore of critical importance to public health.

Even though lock-down measures appear to have significantly reduced the current rate of infection in the UK, healthcare workers will continue to be at risk of contracting COVID-19, especially as measures are relaxed, added Professor Martin Llewelyn, Brighton and Sussex Medical School and lead COPCOV UK Investigator.

Whilst we wait for an effective and widely available vaccine, the race is on to find a well-tolerated preventative treatment. The results from COPCOV are expected later this year and, if they show that hydroxychloroquine can reduce the chances of catching COVID-19, this would be incredibly reassuring for myself and my frontline colleagues.

Read the original here:
First UK healthcare worker to enrol in COVID-19 prevention trial - PharmaTimes

Read More...

Meet Dr. Wilma Wooten, who wrote the plan to open San Diego restaurants and shops – The San Diego Union-Tribune

May 27th, 2020 11:46 am

The buck arguably stops with Dr. Wilma Wooten as the San Diego region starts to reopen its economy amid the worst pandemic in a century.

Wooten, the countys public health officer, cleared the way this week for resuming in-person dining at restaurants, as well as shopping at retail stores and swap meets. Her plan, which received state approval on Wednesday, makes San Diego the largest county in California to move ahead on Gov. Gavin Newsoms official timeline for easing lockdown conditions.

So far, the region has fared notably well under Wootens leadership when it comes to fending off the new coronavirus. Hospitals have not been overwhelmed with sick patients, and while its taken time, testing capacity and contact tracing appear to be ramping up.

Still, the largest challenge for the 63-year-old Alabama native may lie ahead. As corporate heavyweights and small business owners push for commerce to resume, health experts have said hospitals should brace for a spike in illnesses and deaths.

Wooten is a widely respected medical professional who received high praise for her handling of the 2009 swine flu outbreak that started in San Diego, but her political skills could be tested. Four years ago, she was thrust into the spotlight when a rash of hepatitis A cases ripped through the local homeless community. A state audit found she mishandled the crisis by not forcing the city to deal with the outbreak sooner and more forcefully.

A spate of new COVID-19 cases could force Wooten into a faceoff with elected leaders eager to please their out-of-work constituents something she says shes prepared for.

It will be difficult to dial back, but we will have to if things get out of hand, she said during an interview Thursday. This is a challenge of all health officers across the nation.

So far, disagreements over tackling the coronavirus pandemic have been relatively minor, such as when conservative Supervisor Jim Desmond recently downplayed the seriousness of the coronavirus outbreak by pointing out that all but six of the countys fatalities involved underlying health conditions.

Dr. Wilma Wooten, San Diego County public health officer

Wooten quickly rebutted the supervisors comments at one of the countys regular press briefings, saying that the lives of those with existing medical conditions were no less valuable than others.

Still, Desmond is not alone in his push to loosen restrictions far beyond what Newsom and his team in Sacramento have called for. San Diego Mayor Kevin Faulconer and the entire Board of Supervisors save its lone progressive, Supervisor Nathan Fletcher have called for reopening the economy far beyond what the state and the health officer appear comfortable with.

Wooten, with Fletchers support, has repeatedly called for following the guidance of state leaders as well as the Centers for Disease Control and Prevention.

We are very sensitive of the importance to balance protection of the publics health with economic viability, and we are following the governors guidance, she said.

That message comes in contrast to a letter recently penned by San Diego Mayor Kevin Faulconer and Supervisor Greg Cox urging the governor to allow local jurisdictions to control the speed at which they reopen.

Our businesses are ready to thoughtfully reopen and adapt with necessary protective measure, but they need to be provided that opportunity, the letter reads in part.

Wooten grew up with what she described as meager means in Thomaston, Ala., a rural town of fewer than 1,000 people and one streetlight.

Raised by her great grandparents, she and her brother spent a lot of time helping the local elderly community. She said the experience helped her develop an enduring sense of public service, and from a young age, she knew she wanted to get into medicine.

Valedictorian of her high school class, she attended Spelman College in Atlanta. Before graduating from the historical black college for women in 1978, she met Roslyn Crisp, who would become her lifelong friend.

Crisp, a 63-year-old pediatric dentist from North Carolina, said they mostly avoided parties and focused on their academic careers. They still see each other a few times a year and regularly vacation together.

She has the qualities that I think anybody would want in a friend, Crisp said of Wooten. Shes very compassionate. Shes understanding. Shes a good listener.

If she gives you an opinion, honestly, I really feel like she has thought it out, and shes done her homework.

Wooten went on to attended the University of North Carolina School of Medicine, where she graduated with a degree in medicine in 1986. She did her residency at the recently closed Providence Hospital in Washington, D.C.

She came to San Diego in 1989 to do her residency in preventative medicine at San Diego State University under Dr. Kevin Patrick, now a professor emeritus of family medicine and public health at the UC San Diego School of Medicine.

A year later on Patricks advice, Wooten applied to work at UCSD and was hired to, among other things, research family and preventive medicine.

She was very practical in her approach to things and very hard working, Patrick recalls. Obviously, she cares for the community. I think the social justice component was really important for Wilma.

Wooten was hired by San Diego County in 2001 to serve as deputy health officer. At the time, she was also volunteering on medical trips to Jamaica, Kenya and Ghana to treat and educate patients vulnerable to communicable diseases, such as AIDS.

In 2007, she was elevated to public health officer, overseeing the countys Public Health Services agency, which currently has about 500 employees and a $100 million budget. She currently makes a salary of $270,836 a year.

Her first big challenge came in 2009, when San Diego became ground zero for the countrys H1N1 swine-flu epidemic. Wooten would later win a national Public Health Heroes award for her work.

She is one of my public-health heroes, said Dr. Ron Chapman, public health officer for Californias Yolo County. He serves with her on the Public Health Accreditation Board. Dr. Wooten is brilliant, insightful, caring, and a strategic thinker.

Dr. Wilma Wooten showed the proper way to cough during a 2009 briefing on the H1N1 flu death of a county resident.

In March 2017, Wooten declared an outbreak of hepatitis A, which was infecting homeless people and illegal drug users through feces. Nobody knew at the time, but it would become the countrys worst eruption of the disease since a vaccine was introduced in 1995.

What happened over the next six months led to intense media scrutiny and finger pointing between county officials and San Diego Mayor Kevin Faulconers team.

While the county would later suggest the city dragged its feet on sanitation, the mayors team faulted the county for not taking charge during the outbreak.

This is a dark stain on our communitys civic record, said Assemblyman Todd Gloria, D-San Diego. Hepatitis is a disease that we know a lot about, that we have tests for, that we have a vaccine for. The fact that it killed 20 people and infected over 500 more was a real indictment of our public health infrastructure.

At the time, the city much like other parts of Southern California that experienced simultaneous, albeit smaller outbreaks of hepatitis A had long been entwined in a debate about whether homeless communities had adequate access to toilets and proper sanitation.

Advocates had routinely criticized Faulconer for not increasing the number of public toilets downtown, citing grand jury reports from 2010 and 2015 that warned unsanitary conditions in the city could lead to an outbreak of disease.

The issue became a political hot potato, with residents and local business owners complaining that public toilets invited unsavory behavior. In 2015, the mayor removed one of two metal toilets downtown, known as Portland Loos, which had cost the city roughly $560,000. The second loo was then removed at the height of the hepatitis outbreak.

Assemblyman Todd Gloria, D-San Diego

Wooten issued the first public health directive of her career on Aug. 31, 2017, calling on the city of San Diego to expand access to public restrooms and hand-washing stations, as well as to ramp up street-cleaning efforts.

The next day she declared a health emergency, and Faulconer made his first public statements on the issue, despite that fact that the city had quietly warned its own workers for months about the danger of infection.

Nobody wanted to take the lead, recalled Michael McConnell, a prominent local advocate for the homeless. Nobody wanted to be in charge of this thing, and on the ground it was just a train wreck.

Wooten and her team ramped up a vaccination program that eventually helped stem the outbreak.

However, California State Auditor Elaine Howle released a report in 2018 that found they should have acted faster. It faulted both the city and the county for not tackling sanitation earlier, but called out the county for being too lenient with Faulconers team.

The county health officer did not issue a directive sooner because she wanted to collaborate with the city instead of mandating its compliance, the report read. However, by exercising her legal authority before August 31, 2017, the county health officer likely would have prompted the city to implement the important sanitation measures sooner.

Gloria and Assemblywoman Lorena Gonzalez, D-San Diego, co-authored a bill in response to the audit report that cemented a local health officers authority to compel other government agencies to take action to curb the spread of disease.

According to the audit report, the countys own legal counsel questioned Wootens authority to issue Faulconer the health directive.

Neither Wooten nor Faulconer want to relitigate the hepatitis A crisis, citing the need to collaborate during the current pandemic.

That happened, and were in a different place now, and we have a great relationship with actually all of the municipalities that are in San Diego County, Wooten said.

Wooten has been much more visible in the current crisis, and the stakes are much higher due to the weeks-long shutdown of the economy and pressure to reopen it. She and other officials are giving regular video updates on Facebook and Twitter concerning issues that intimately impact the lives of nearly everyone in the county, from wearing face masks to opening local beaches.

The relationships been a bit rocky at times.

Wooten, for example, suggested in a press briefing this month that she would block casinos on tribal lands from reopening, saying: We feel that the health officers order does extend to our tribal nations in this particular situation.

Wooten reversed her position the next day after meetings with tribal leaders, acknowledging that, Tribal nations have sovereign authority, so our plan is to provide guidance and advice where possible.

In an appearance at the Rock Church on March 15, Wooten dismissed the idea that the virus could be spread by those without symptoms.

Oh, I heard that it was that you could without symptoms, said Pastor Miles McPherson during an exchange.

There are a lot of rumors and misinformation out there, Wooten responded. Even if theyve been exposed to someone who did have symptoms, if they do not have symptoms, others who have come in contact with that individual should be at low or no risk for developing the disease.

At the time, evidence of asymptomatic transmission was just starting to percolate. Its now believed that has played a significant role in spreading the virus. Wooten was not technically wrong about the state of research at the time, as shes quick to point out.

That was not a misstep, Wooten told the Union-Tribune. That was based on the facts that we had that day.

County public health officer Wilma Wooten M.D., and other officials, provide the latest updates on COVID-19 Coronavirus at the County Operations Center on February 14, 2020 in San Diego, California.

(Eduardo Contreras/The San Diego Union-Tribune)

Now Wooten has taken another bold leap into the unknown.

On Tuesday, she submitted a plan to the state for reopening restaurants, retail businesses and swap meets. Officials in Sacramento approved the plan the next day, making San Diego a test case for lifting stay-at-home orders in a highly urbanized area.

While Los Angeles County doesnt currently appear to meet the states requirements for reopening such businesses, several Bay Area counties seemingly do but have chosen to remain under lockdown, including Marin, San Mateo, Contra Costa, Sonoma and San Francisco.

San Diego has fared reasonably well during the pandemic, with about 6,300 cases and about 240 deaths as of Friday. Still, the decision to reopen comes at a time when the region is barely meeting the states benchmarks for doing so.

For example, the state has required as a condition for reopening such businesses that San Diego County be testing at least 4,950 people for the virus a day, or 1.5 people per 1,000 residents. The county reports that its currently testing only about 4,000 people a day on average, although it expects to meet or exceed the states benchmark by June.

The state has also called for counties to have enough open hospital beds to accommodate a surge in COVID-19 patients of roughly 35 percent. San Diego County currently has just enough free space across its 24 hospitals to meet the requirement, according to the report.

Theres also a question about whether the San Diego has enough contact tracers to be able to isolate infection clusters before they get out of control.

The state has called on counties to have at least 15 contact tracers for every 100,000 residents in order to open shops and eateries. That would be roughly 500 trained professionals for the San Diego region. Currently, the county reports that it has only 87 tracers, although its says the county has hired another 329 tracers that are currently completing their training. San Diego State University will also provide another 100 tracers at some point, according to the county.

Still, Wootens plan for reopening certain businesses appears to have the support of the local medical community. UC San Diego Health CEO Patty Maysent called the plan on Tuesday incredibly thoughtful.

I think it addresses the main issues that we need to follow, she said. The metrics that are laid out in the plan are in my mind pretty factually based.

The plan also has the backing of Fletcher, who appears to be Wootens firewall against politicians who would swing the doors open on the economy tomorrow if they could.

Dr. Wooten is one of the hardest-working public servants that Ive encountered in my time working in government, he said. She works on these issues of public health every single day, seven days a week, all day long.

Read more here:
Meet Dr. Wilma Wooten, who wrote the plan to open San Diego restaurants and shops - The San Diego Union-Tribune

Read More...

Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function | CIA – Dove Medical Press

May 27th, 2020 11:46 am

Naoki Yuda,1 Miyuki Tanaka,1 Koji Yamauchi,1 Fumiaki Abe,1 Izumi Kakiuchi,2 Kyoko Kiyosawa,2 Mitsunaga Miyasaka,2 Naoki Sakane,3 Masahiko Nakamura4

1Food Ingredients and Technology Institute, Morinaga Milk Industry Co., Ltd., Zama, Kanagawa, Japan; 2Department of Nursing, Matsumoto Junior College, Matsumoto, Nagano, Japan; 3Division of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan; 4Matsumoto City Hospital, Matsumoto, Nagano, Japan

Correspondence: Naoki YudaFood Ingredients and Technology Institute, Morinaga Milk Industry Co., Ltd., 1-83, 5-Chome, Higashihara, Zama, Kanagawa, JapanTel +81 46 252 3051Fax +81 46 252 3017Email n-yuda@morinagamilk.co.jp

Background: Preventative measures have recently been taken to reduce the incidence of Alzheimers disease worldwide. We previously showed that Met-Lys-Pro (MKP), a casein-derived angiotensin-converting enzyme inhibitory peptide with the potential to cross the bloodbrain barrier, attenuated cognitive decline in a mouse model of Alzheimers disease. However, the effect of MKP on cognitive function improvement in humans remains unknown. This exploratory study sought to investigate whether MKP intake could improve cognitive function in adults without dementia.Methods: A total of 268 community-dwelling adults without dementia participated in this 24-week randomized controlled trial. Participants were randomly allocated to the MKP (n = 134) or placebo (n = 134) group. The MKP group received four tablets daily, each containing 50 g MKP, while the placebo group received four dextrin tablets containing no detectable MKP for 24 weeks. Scores on the Japanese version of the cognitive subscale of the Alzheimers Disease Assessment Scale (ADAS-cog) were used as the primary outcome to compare cognitive function between the MKP and placebo groups. The study products were also evaluated for safety.Results: The intention-to-treat analysis showed that there was no significant difference between the groups in terms of the ADAS-cog total score. Orientation, as measured by the respective ADAS-cog subscale, was significantly improved compared to placebo at 24 weeks post-MKP administration (P = 0.022). No serious adverse events due to MKP intake were observed.Conclusion: To the best of our knowledge, this is the first study to report the effects of MKP on human cognition. These preliminary results suggested the safety of daily MKP intake and its potential to improve orientation in adults without dementia. Further clinical studies are needed to confirm the present findings and the benefits of MKP on cognitive function.

Keywords: humans, MKP, cognition, cognitive dysfunction, orientation, Alzheimers disease

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continued here:
Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function | CIA - Dove Medical Press

Read More...

HCQ breakthrough: ICMR finds its effective in preventing coronavirus, expands its use – ThePrint

May 27th, 2020 11:46 am

Text Size:A- A+

New Delhi: The Indian Council of Medical Research (ICMR), the countrys apex body in the field, has found that consuming the drug hydroxychloroquine reduces the chances of getting infected with Covid-19.

As a result, ICMR released an advisory Friday to expand the usage of HCQ an anti-malarial drug as a preventive treatment against the novel coronavirus.

The conclusion has been drawn on the basis of three studies conducted by the ICMR.

The advisory suggests surveillance workers, paramilitary and police personnel, as well as medical staff working in non-Covid hospitals and blocks to start consuming the pill as preventive therapy.

ICMR had issued an advisory to begin using HCQ in March, but it had drawn criticism for lacking scientific evidence that the drug works against the novel coronavirus.

Also read: How the humble hydroxychloroquine has become Indias unlikely new global strategic asset

According to the advisory, the premier health body undertook investigation at three central government hospitals in New Delhi. While it did not reveal the names of the hospitals, it said the investigation indicates that amongst healthcare workers involved in Covid-19 care, those on HCQ prophylaxis were less likely to develop SARS-CoV-2 infection, compared to those who were not on it.

The advisory also states that the National Institute of Virology in Pune has found in laboratory testing that HCQ reduces the viral load.

The ICMR also analysed data collected previously, known as retrospective case-control analysis, and found a significant relationship between the number of doses taken and frequency of occurrence of Covid-19 infection in symptomatic healthcare workers who were tested for SARS-CoV-2 infection.

It further said the benefit was less pronounced in healthcare workers caring for a general patient population.

Another observational study was conducted among 334 healthcare workers at the countrys largest public hospital, New Delhis All India Institute of Medical Sciences (AIIMS). The 248 workers who took HCQ as preventive drug for an average of six weeks had lower incidence of the infection than those not taking the pill.

Based on the findings of the studies, the government has decided to administer the drug as a prophylaxis or preventive therapy to asymptomatic healthcare workers working in non-Covid hospitals as well as non-Covid blocks of hospitals earmarked for Covid treatment.

Asymptomatic frontline workers, such as surveillance workers deployed in containment zones, as well as paramilitary and police personnel involved in Covid-related activities will be asked to pop HCQ pills.

Until now, only high-risk individuals, including asymptomatic healthcare workers involved in containment and treatment of Covid-19 patients, and asymptomatic household contacts of laboratory-confirmed cases, were being administered the drug. They will continue to consume the drug.

While the dosage will remain the same as before, eight weeks, the ICMR advisory suggests that it can be used beyond that period as well, but with close monitoring.

With available evidence for its safety and beneficial effect as a prophylactic drug against SARS-CoV-2 during the earlier recommended 8 weeks period, the experts further recommended for its use beyond 8 weeks on weekly dosage with strict monitoring of clinical and ECG parameters, which would also ensure that the therapy is given under supervision, it stated.

In clinical practice, HCQ is commonly prescribed in a daily dose of 200mg to 400mg for treatment of diseases such as rheumatoid arthritis and systemic lupus erythematosus for prolonged treatment periods with good tolerance, the advisory added.

The ICMR had earlier announced that some side effects, such as abdominal pain and nausea, have been observed in healthcare workers who were administered HCQ.

The anti-malaria drug isoften blamed for triggering irregular heartbeat.

However, in the final results of the studies (HCQ prophylaxis among 1,323 healthcare workers), the ICMR found mild adverse effects such as nausea in 8.9 per cent workers, abdominal pain in 7.3 per cent, vomiting in 1.5 per cent, low blood sugar (hypoglycaemia) in 1.7 per cent and cardio-vascular effects in 1.9 per cent.

The advisory states the drug should be discontinued if it causes the rare side effects related to the heart, such as cardiomyopathy, a disease which makes it harder for heart to pump blood to the entire body, and heart-rate disorders.

The advisory mentions that HCQ, in rare cases, can cause visual disturbance, including blurring of vision, which is usually self-limiting and improves on discontinuation of the drug.

ICMR has clarified that for the above cited reasons heart and vision the drug has to be given under strict medical supervision with an informed consent.

Also Read: Ashwagandha the new HCQ? Modi govt begins study to see if herb keeps coronavirus away

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Subscribe to our YouTube channel.

Original post:
HCQ breakthrough: ICMR finds its effective in preventing coronavirus, expands its use - ThePrint

Read More...

Research Report with COVID-19 Forecasts – Neuropathy Pain Treatment Market 2020-2024 | Presence Of Large Patient Pool To Boost Growth | Technavio -…

May 27th, 2020 11:45 am

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the neuropathy pain treatment market and it is poised to grow by USD 1702.89 mn during 2020-2024, progressing at a CAGR of almost 5% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, Assertio Therapeutics Inc., AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The presence of a large patient pool has been instrumental in driving the growth of the market.

Neuropathy Pain Treatment Market 2020-2024 : Segmentation

Neuropathy Pain Treatment Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43322

Neuropathy Pain Treatment Market 2020-2024 : Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our neuropathy pain treatment market report covers the following areas:

This study identifies the growing focus on the development of drugs for the treatment of diabetic neuropathy pain as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years.

Neuropathy Pain Treatment Market 2020-2024 : Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the neuropathy pain treatment market, including some of the vendors such as Abbott Laboratories, Assertio Therapeutics Inc., AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi Backed with competitive intelligence and benchmarking, our research reports on the neuropathy pain treatment market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Neuropathy Pain Treatment Market 2020-2024 : Key Highlights

Table Of Contents :

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Indication

Market Segmentation by Drug Class

Customer Landscape

Geographic Landscape

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read this article:
Research Report with COVID-19 Forecasts - Neuropathy Pain Treatment Market 2020-2024 | Presence Of Large Patient Pool To Boost Growth | Technavio -...

Read More...

Page 532«..1020..531532533534..540550..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick